You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
据报欧洲审核印度疫苗生产商 为增加阿斯利康疫苗供应铺路
阿思达克 03-01 16:40
《路透社》引述消息人士报道,欧洲药物监管机构正在审核印度血清研究所(SII)的生产基地,如果审核通过,意味着阿斯利康(AstraZeneca)的疫苗可以出口到欧盟。

SII是世界上最大的疫苗生产商,正在为数十个贫困及中等收入国家生产阿斯利康与牛津大学合作研发的疫苗。

目前欧盟及英国的疫苗主要由当地生产商供货,但由於生产出现问题导致阿斯利康减少对欧盟的供货。

欧洲医药管理局(EMA)及欧盟执委会拒绝回应报道,确认若疫苗需要出口到欧盟,需要获得EMA对产地的审批并改变市场销售许可。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account